VirusExpress® 293 AAV Production Platform Brochure

The VirusExpress® 293 AAV Production Platform offers a transfection-based solution using a suspension-adapted cell line, which is GMP banked and characterized as a chemically defined medium, and a process with proven performance at a clinically relevant scale.

The challenges faced by AVV manufacturers can be alleviated with a scalable AAV manufacturing offering. The VirusExpress® AAV platform includes an optimized medium for transient transfection, suspension-adapted cells, and bioreactor process development and scale-up. The VirusExpress® 293 AAV Production cells have been single-cell cloned and have been suspension adapted into chemically defined cell culture medium (EX-CELL® CD HEK293 Viral Vector Medium, 14385C). The cell bank was manufactured and characterized under GMP regulations (21 CFR 210, 211, 600, and 610). And the process development has been proven up to 3L production scale as well as cell growth up to 50 L scale.

In this brochure, we discuss how our 30+ years of viral vector experience can help bring your gene therapy to life.